Compare APGE & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APGE | IRTC |
|---|---|---|
| Founded | 2022 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.8B |
| IPO Year | 2023 | 2016 |
| Metric | APGE | IRTC |
|---|---|---|
| Price | $83.75 | $117.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 13 |
| Target Price | $109.67 | ★ $207.54 |
| AVG Volume (30 Days) | ★ 1.1M | 532.1K |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.71 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $747,138,000.00 |
| Revenue This Year | N/A | $19.58 |
| Revenue Next Year | N/A | $15.95 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 26.24 |
| 52 Week Low | $26.20 | $92.52 |
| 52 Week High | $85.94 | $210.01 |
| Indicator | APGE | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 62.90 | 39.86 |
| Support Level | $73.06 | $112.31 |
| Resistance Level | N/A | $124.40 |
| Average True Range (ATR) | 4.54 | 4.60 |
| MACD | 1.23 | 1.31 |
| Stochastic Oscillator | 88.18 | 40.28 |
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
iRhythm Holdings Inc formerly, iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.